Serum lipid profile abnormalities among beta-thalassemia patients: a systematic review and meta-analysis.

IF 3.9 2区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Lipids in Health and Disease Pub Date : 2024-11-25 DOI:10.1186/s12944-024-02377-6

Sagad O O Mohamed, Ali E A Mohamed, Mohamed S K Salih, Khalid S K Salih, Ahmed S E E Abdelrahman, Ahmed G A Abdelgadir, Mona G A Ahmedkaroum, Gehad A Abdalla, Hanaa A M Fadil, Mahmoud A M Abdelrahman, Nehal S A Salih

{"title":"Serum lipid profile abnormalities among beta-thalassemia patients: a systematic review and meta-analysis.","authors":"Sagad O O Mohamed, Ali E A Mohamed, Mohamed S K Salih, Khalid S K Salih, Ahmed S E E Abdelrahman, Ahmed G A Abdelgadir, Mona G A Ahmedkaroum, Gehad A Abdalla, Hanaa A M Fadil, Mahmoud A M Abdelrahman, Nehal S A Salih","doi":"10.1186/s12944-024-02377-6","DOIUrl":null,"url":null,"abstract":"Background: Patients with betathalassemia have higher risk of various metabolic disturbances. The literature presents conflicting results about the patterns of abnormal lipid profile among patients with betathalassemia. This systematic review aimed to assess dyslipidemia patterns among patients with betathalassemia when compared with healthy individuals.Methods: The methods used were adherent to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. Systematic searches of the literature were done across Medline/PubMed, Web of Science, Science Direct, and Regional Portal of the World Health Organization Virtual Health Library. Calculation of standardized mean difference (SMD) estimates and their associated 95% confidence intervals (CIs) were done through Jamovi software.Results: The systematic review included 21 studies meeting the criteria for the analyses. Patients with beta-thalassemia major displayed significantly elevated triglyceride levels (SMD: 0.448, 95% CI, 0.214 to 0.682; P < .001) and reduced total serum cholesterol (SMD: -2.26 (95% CI-2.834 to -1.678; P < .001), as well as decreased levels of both low-density lipoprotein cholesterol (SMD: -1.88, 95% CI, -2.614 to -1.147; P < .001) and high-density lipoprotein cholesterol (SMD: -1.32, 95% CI, -1.786 to -0.860; P < .001). Similarly, beta-thalassemia intermedia patients exhibited comparable lipid profile abnormalities to those with beta-thalassemia major. Conversely, beta-thalassemia minor patients only showed significantly lower total serum cholesterol levels (SMD: -0.66, 95% CI, -0.860 to -0.472; P < .001).Conclusion: Evidence indicates alterations in lipid profile markers among beta-thalassemia patients. The findings indicate the importance of assessing hypertriglyceridemia and hypocholesterolemia in these patients, especially those with major and intermedia forms, as these lipid profile abnormalities increase the risk of cardiovascular disease.","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"388"},"PeriodicalIF":3.9000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587755/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lipids in Health and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12944-024-02377-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with betathalassemia have higher risk of various metabolic disturbances. The literature presents conflicting results about the patterns of abnormal lipid profile among patients with betathalassemia. This systematic review aimed to assess dyslipidemia patterns among patients with betathalassemia when compared with healthy individuals.

Methods: The methods used were adherent to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. Systematic searches of the literature were done across Medline/PubMed, Web of Science, Science Direct, and Regional Portal of the World Health Organization Virtual Health Library. Calculation of standardized mean difference (SMD) estimates and their associated 95% confidence intervals (CIs) were done through Jamovi software.

Results: The systematic review included 21 studies meeting the criteria for the analyses. Patients with beta-thalassemia major displayed significantly elevated triglyceride levels (SMD: 0.448, 95% CI, 0.214 to 0.682; P < .001) and reduced total serum cholesterol (SMD: -2.26 (95% CI-2.834 to -1.678; P < .001), as well as decreased levels of both low-density lipoprotein cholesterol (SMD: -1.88, 95% CI, -2.614 to -1.147; P < .001) and high-density lipoprotein cholesterol (SMD: -1.32, 95% CI, -1.786 to -0.860; P < .001). Similarly, beta-thalassemia intermedia patients exhibited comparable lipid profile abnormalities to those with beta-thalassemia major. Conversely, beta-thalassemia minor patients only showed significantly lower total serum cholesterol levels (SMD: -0.66, 95% CI, -0.860 to -0.472; P < .001).

Conclusion: Evidence indicates alterations in lipid profile markers among beta-thalassemia patients. The findings indicate the importance of assessing hypertriglyceridemia and hypocholesterolemia in these patients, especially those with major and intermedia forms, as these lipid profile abnormalities increase the risk of cardiovascular disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

地中海贫血症患者血清脂质异常：系统综述和荟萃分析。

背景：地中海贫血患者出现各种代谢紊乱的风险较高。关于地中海贫血患者血脂异常的模式，文献给出了相互矛盾的结果。本系统综述旨在评估与健康人相比，地中海贫血患者的血脂异常模式：采用的方法符合系统综述和荟萃分析首选报告项目（PRISMA）指南。对 Medline/PubMed、Web of Science、Science Direct 和世界卫生组织虚拟健康图书馆区域门户网站上的文献进行了系统检索。通过 Jamovi 软件计算标准化平均差 (SMD) 估计值及其相关的 95% 置信区间 (CI)：系统综述包括 21 项符合分析标准的研究。重型β地中海贫血患者的甘油三酯水平明显升高（SMD：0.448，95% CI，0.214 至 0.682；P 结论：有证据表明血脂谱发生了改变：有证据表明，β-地中海贫血患者的血脂指标发生了改变。研究结果表明，评估这些患者（尤其是重型和中型患者）的高甘油三酯血症和低胆固醇血症非常重要，因为这些血脂异常会增加罹患心血管疾病的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lipids in Health and Disease 生物-生化与分子生物学

CiteScore

7.70

自引率

2.20%

发文量

122

审稿时长

3-8 weeks

期刊介绍： Lipids in Health and Disease is an open access, peer-reviewed, journal that publishes articles on all aspects of lipids: their biochemistry, pharmacology, toxicology, role in health and disease, and the synthesis of new lipid compounds. Lipids in Health and Disease is aimed at all scientists, health professionals and physicians interested in the area of lipids. Lipids are defined here in their broadest sense, to include: cholesterol, essential fatty acids, saturated fatty acids, phospholipids, inositol lipids, second messenger lipids, enzymes and synthetic machinery that is involved in the metabolism of various lipids in the cells and tissues, and also various aspects of lipid transport, etc. In addition, the journal also publishes research that investigates and defines the role of lipids in various physiological processes, pathology and disease. In particular, the journal aims to bridge the gap between the bench and the clinic by publishing articles that are particularly relevant to human diseases and the role of lipids in the management of various diseases.